Phase II study of preoperative endocrine therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients

被引：0
|
作者：
Semigiazov, Vladimir F. [1 ]
Ivanov, Vadim G. [1 ]
Bozhok, Alla A. [1 ]
Semiglazov, Vjacheslav V. [1 ]
Melnikova, Olga A. [1 ]
Kletzel, Alexander A. [1 ]
Topuzov, Eldar E. [1 ]
Paltuev, Ruslan M. [1 ]
Dashian, Garik A. [1 ]
Berstein, Lev M. [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：55 / 55
页数：1
相关论文
共 50 条
  • [21] What is the best therapy for ER-positive breast cancer?
    不详
    [J]. EJC SUPPLEMENTS, 2004, 2 (09): : 62 - 64
  • [22] Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients
    Wang, Wei-Quan
    Zhang, Lei
    Yang, Fang
    Zhou, Hong-Hao
    Zhang, Wei
    Zou, You
    Liu, Rong
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2022, 155
  • [23] The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients
    Bièche, I
    Parfait, B
    Noguès, C
    Andrieu, C
    Vidaud, D
    Spyratos, F
    Lidereau, R
    Vidaud, M
    [J]. ONCOGENE, 2001, 20 (47) : 6955 - 6959
  • [24] The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients
    Ivan Bièche
    Béatrice Parfait
    Catherine Noguès
    Catherine Andrieu
    Dominique Vidaud
    Frédérique Spyratos
    Rosette Lidereau
    Michel Vidaud
    [J]. Oncogene, 2001, 20 : 6955 - 6959
  • [25] The role of ELF3 in acquired resistance to endocrine therapy in ER-positive breast cancer
    Zhang, Na
    Zheng, Rongbin
    Brown, Myles
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [26] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [27] Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
    Jeong, Hyehyun
    Kim, Sung-Bae
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [28] Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database
    LeVasseur, Nathalie
    Willemsma, Kaylie-Anne
    Li, Huaqi
    Gondara, Lovedeep
    Yip, Walter C.
    Illmann, Caroline
    Chia, Stephen K.
    Simmons, Christine
    [J]. CLINICAL BREAST CANCER, 2019, 19 (06) : E683 - E689
  • [29] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [30] Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study].
    Kim, Jisun
    Han, Wonshik
    Kim, Eun-Kyu
    Jung, Yongsik
    Kim, Hyun-Ah
    Chae, Soo Min
    Lee, Eun Sook
    Ahn, Sei-Hyun
    Kim, Tae Hyun
    Jeong, Joon
    Choi, Su Yun
    Nam, Seok Jin
    Paik, Nam-Sun
    Kim, Lee Su
    Gong, Gyungyub
    Yu, Jong Han
    Jung, So-Youn
    Kim, Hee Jeong
    Ahn, Sung Gwe
    Kim, Min Kyoon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345